drugset / Trial / NCT01531829
Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD
Phase 4
Unknown
460 enrolled
Beijing Chao Yang Hospital
Ministry of Science and Technology of the People´s Republic of China · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
In selected patients with acute pulmonary embolism(PE), low dose (50mg/2h) recombinant tissue plasminogen activator (rt-PA) regimen had been reported to have less bleeding tendency than the FDA-approved rt-PA 100mg/2h regimen 100mg/2h regimen (3% vs.10%), it is worthwhile to reveal whether low dose rt-PA plus low molecular weight heparin (LMWH) can rapidly reverses RV pressure overload in PE, but not increase bleeding and other adverse events. The aim of the study is to compare thrombolytic treatment with LMWH in patients with acute normotensive PE with right ventricular dysfunction(RVD).
Timeline
- Start
- 2009-07
- Primary completion
- 2012-07
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alteplase | Protein / enzyme biologic | 50 mg | — |
| Comparator | Nadroparin Calcium | Other / unclassified | 0.1 ml | — |